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Since the late 1960s, hundreds of parent support and 
patient advocacy groups related to specific disorders 
have been formed.[2] Many of these disorders have 
a genetic basis, and with the amazing advances in 
human/medical genetics, more and more issues and 
ideas, opportunities and potential therapies have become available. 
With the advent of the internet, social networking and universal 
e-mail, the potential for family-to-family communication has 
expanded exponentially. The opportunity to learn from other families 
and other patient advocacy groups is enormous. The real challenge 
has been one of determining the accuracy of the information that 
is available. That is where knowledgeable healthcare professionals 
become important – to give expert advice.
Groups have sprung up all over the globe. If they are related to the 
same disorder, interested individuals communicate freely, sharing 
medical information, diagnostic information, practical aspects about 
living with the disorder, the natural history and potential therapies, 
all in new and engaging ways.[3-4]
Such groups are usually started by a single individual seeking 
information, who reaches out to others. It may be an affected 
person, a parent, a grandparent, or another family member. Often 
a group starts when two or three people ‘connect’ and share 
information, experiences and ideas. They often evolve into more 
formal organisations with by-laws and non-profit status, and with 
healthcare professionals/medical advisors in partnership. Most of 
these organisations are totally voluntary, although as they grow and 
move into fundraising they may require an executive officer and after 
years of successful operation may have an office and staff.[5]
Parent support group activities
The types of activities of parent support groups include:
• Information sharing through public and family education, often 
involving conferences, workshops and meetings where networking 
can take place; a newsletter that provides information, new 
research results, personal experiences, fundraising opportunities, 
etc.; and postings on websites of all types of information, together 
with references
• Most groups support and encourage research on ‘their’ disorder by 
participating in research studies, often assisting in the study design 
(as part of the new community-based research process). They 
may also solicit volunteers and control subjects, help to collect the 
data, and even help with the analysis. Some groups raise money to 
support both basic and clinical research as well.
• Most groups are interested in developing and updating guidelines 
for care of individuals affected with the disorder (which of course 
depends on the results of the research). Care guidelines involve 
knowledge about the natural history of the disorder and the 
appropriate therapies and management.
• Most groups have social events, including meeting other families. 
Such events provide emotional support and the opportunity to 
meet other affected individuals, particularly of different ages.
• Some groups take on the role of advocating for research concerning 
new therapies for ‘their’ disorder. Most of these disorders fit into the 
‘rare disease’ category.[6-9] Often an organisation will bring together 
a surprisingly large number of affected individuals who are willing 
to take part in research projects. The advocacy can be for research 
regarding natural history information, for management and care, or 
for therapy.[10-11] Once some type of therapy is available (symptomatic, 
corrective, molecular or genetic), the advocacy component may then 
be related to raising funding for treatment for all affected individuals.
• Many groups take part in creating a registry of affected individuals 
or a biobank of specimens.[5] A recent study by Landy et al.[12] 
surveyed disease advocacy organisations and identified the kinds 
of research engagement.
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By the second decade of the 21st century, most clinical geneticists 
are both aware of and involved in patient advocacy and parent 
support groups. During my training in medical genetics, I worked 
with Dr Victor McKusick, just as he was becoming involved with 
Little People of America (LPA), to study chondrodysplasia. In many 
ways, LPA is a particularly good model for how special interest 
patient support groups function. I gained additional insight in 1995 
when I was the Philip von Wielligh Lecturer in South Africa, at 
Trefor Jenkins’ invitation, visiting Pretoria, Durban, Cape Town 
and Johannesburg. My visit was sponsored by the Southern African 
Inherited Disorders Association (SAIDA), which had been formed 
20 years earlier in 1975, primarily to undertake Tay-Sachs carrier 
screening. However, once families became involved, they realised 
there was a much broader spectrum of genetic disorders – each 
relatively rare – and they saw the power of their collaboration.[1] 
Each family, of course, is interested in ‘their disorder’, but there is 
so much they can learn from each other.
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• Finally, because families are highly motivated to learn about ‘their’ 
disorder/disease, they use their IT skills to scan and keep track of 
new medical/research developments, even informing researchers 
and their physicians about new developments. They also inform 
members of their group about new developments, leading to 
improved treatment for the members. Families and affected 
individuals sometimes make their own hypotheses about cause and 
effect, often spurring on research studies.
Medical advisors
Such groups need accurate and reliable medical information, so 
they usually engage knowledgeable healthcare professionals with 
whom they work.[13-14] Lin et al.[15] surveyed a group of genetic 
healthcare professionals and found that 95% serve on a medical 
advisory board for one or another patient support group. Most are 
volunteers without pay, and most have taken part in producing 
educational materials and guidelines. The concerns of healthcare 
professionals who volunteer for and support genetic lay advocacy 
groups focused on: (i) confidentiality regarding affected individuals 
and their families’ medical information and family history;[15-16] (ii) 
their own potential conflicts of interest;[15] and (iii) any medico-legal 
liability that might arise.[15] 
Because of the large number of genetic disorder support groups, 
alliances between groups have developed in North America and Europe, 
as happened much earlier in South Africa. These alliances[2-4] bring 
small groups and groups that have just started out together with more 
experienced groups so they can learn about organisation, priorities, 
means of communication, and what works and doesn’t work. Most 
importantly, the newer groups can learn how to deal with the growth of 
an organisation over time, how to manage interaction with researchers, 
and how to communicate new information when it becomes available.
Genetic counselling
Clinical/medical geneticists usually work in medical settings to 
provide genetic counselling, which is based on the family and affected 
person’s history,[17-18] laboratory studies, and physical examination. In 
this age of fast-moving information, genetic counselling involves a 
scan of the literature and recent publications, to be as well informed 
as possible.
Genetic counselling has been defined as:[18]
• A ‘communication process’ that deals with human problems 
associated with the occurrence or risk of recurrence of a genetic 
disorder in a family. The process involves comprehending the medical 
facts, including how a diagnosis is made, the probable course of the 
disorder (natural history), and available management (therapy).
• Appreciation of, and understanding of, the ways in which 
heredity contributes to the disorder and the risk of recurrence in 
specific relatives.
• Understanding the alternatives for dealing with the recurrence 
risk (such as prenatal diagnosis, reproductive options, and other 
available alternatives including the types of carrier tests that are 
available or might be developed in the future).
• Helping the family to choose a course of action that is appropriate 
in view of their risk, their family’s goals and their ethical and 
religious standards.
• Helping the family to act in accordance with that decision, 
making the best possible adjustment to the diagnosis. The role 
of the genetic counsellor is helping to identify and deal with the 
associated feelings, and providing support for the decision(s).
Genetic counselling aims to be non-directive, confidential, and without 
personal conflict of interest. There are differences in genetic counselling 
for children and adults that must be considered. In general, it is thought 
that most definitive decisions can wait for maturity and should be left 
until it is possible to engage the affected individual in the decision-making 
process. However, some disorders such as inborn errors of metabolism 
picked up on newborn screening of course require immediate treatment.
A whole variety of new issues have begun to face the genetic 
counsellor (as well as the supportive organisations), such as whether 
to reveal incidental findings,[19] how to engage and warn relatives at 
risk,[20] and the duty to recontact[21] and/or to follow up[22] when new 
research findings could be relevant for the family.
It has become clear through the study of various rare genetic disorders 
that ethnic origin is important both in assessing risk and in the way in 
which genetic counselling is provided.[23-24] This is particularly relevant 
to South Africa, where founder mutations and ethnic group-specific 
mutations have been identified. Consanguinity increases the risk of 
autosomal recessive disorders and stillbirths,[25] and advanced parental 
age clearly increases the risk of new mutations and chromosomal 
abnormalities. Each family responds differently to these complex issues, 
and patient support groups help to identify this type of issue.
Rare genetic disorders
For rare genetic disorders, affected individuals and families 
generally wish to have guidelines for their healthcare.[26] Many 
guidelines have been developed and are available through the 
Canadian College of Medical Genetics, the American College of 
Medical Genetics, the American Academy of Pediatrics and the 
European Society of Human Genetics. In addition, some journals 
specialise in mini-reviews or summaries, such as Clinical Genetics, 
the European Journal of Human Genetics, the New England Journal 
of Medicine and The Lancet.
New developments
The availability of newborn screening raises the possibility of 
screening for treatable disorders, but also for disorders that had not 
previously been screened for, and for which therapies are not yet 
available.[27] The justification for screening for this type of disorder is 
to provide appropriate counselling for the next pregnancy and give 
affected individuals the opportunity to participate in research early in 
the course of the disorder. Family support groups seem to agree with 
this type of justification.
With the advent of directed gene testing and whole-genome 
sequencing, direct-to-consumer testing has become available for 
many disorders.[28] With the goals of commercialising genetics and 
profit making, all these direct-to-consumer tests have major problems 
of interpretation and full genetic counselling. This can be a really 
important issue for families struggling to find a diagnosis.
The advances in genomic medicine have made many new screening 
techniques available, but the interpretation of these findings is often 
difficult[29-30] and requires special expertise. For instance, whole-
genome sequencing identifies hundreds of new genetic changes 
between generations, often making interpretation of results extremely 
difficult. When abnormalities are found with comparative genomic 
hybridisation array in the affected person, parental studies usually 
need to be done and even then it is not always clear how to interpret 
the results. Exomic studies may be equally difficult to interpret.[30]
Availability and the cost to healthcare systems become relevant 
with regard to whether genetic diagnostic tests will actually be 
available to families.[30] Often molecular diagnostic testing will not be 
provided by a healthcare-providing group or system, unless making 
a specific diagnosis will change treatment or reproductive outcomes.
With new forms of testing, a whole range of new ethical issues arise 
concerning confidentiality and privacy, which of course are important 
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to families. Privacy issues tend to interfere with surveillance studies, 
such as determining the incidence of birth defects in a given country 
or population (which families of course want to know). Reporting 
of birth defects to surveillance institutions can interfere with the 
establishment of frequency of these ‘rare’ disorders.[6-8] Another 
important ethical issue is whether children should be allowed to 
take part in research studies. If they are not, research concerning the 
childhood aspect of any disorder may be limited.
Educating newly diagnosed families is a real challenge to healthcare 
providers. Parent support groups and their members are often most 
helpful, since it involves one affected family talking to another. Parent 
support groups provide many different types of resources both to 
medical geneticists and to families with specific diseases.
Progress around the world
In the almost 20 years that have passed since my visit to South Africa, 
sponsored at that time by SAIDA, there have been enormous advances 
in human/medical genetics. Patient advocacy/parent support groups 
have helped to clarify the way in which this new knowledge should 
be used. I am very grateful to SAIDA for the opportunity to have got 
to know and worked with Trefor Jenkins, and to the good families 
around the world that, through their organisations, support our ever-
improving provision of care.
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